Please login to the form below
pioglitazone
This page shows the latest pioglitazone news and features for those working in and with pharma, biotech and healthcare.
Kinarus’ KIN001 shows strong antiviral activity against BA.2 and BA.5 Omicron subvariants
KIN001 is an orally administered combination of two drugs – pamapimod and pioglitazone – that have demonstrated synergistic antiviral and anti-inflammatory activity, as well as ability to reduce tissue fibrosis, a quality
Latest news
-
Another Alzheimer's bust as Merck & Co stops verubecestat study
Since the start of the year, Boehringer Ingelheim has stopped development of its PDE9a inhibitor BI 4093906, Takeda and Zinfandel abandoned efforts to repurpose diabetes drug pioglitazone for the disease, and
-
Boehringer abandons PDE-targeted Alzheimer’s drug
Various other treatment approaches have also been tried and failed, including drugs targeting the serotonin pathway as well as diabetes medicine pioglitazone.
-
Takeda and Zinfandel abandon Alzheimer’s drug
Pioglitazone failed to show therapeutic improvements in late-stage testing. A phase III trial of pioglitazone in Alzheimer’s disease has been terminated by Takeda and partner Zinfandel Therapeutics after it ... Pioglitazone was being tested in people
-
NICE backs freer use of SGLT2 inhibitors for diabetes
The new guidance allows the drugs to be used first-line for people who cannot tolerate metformin, and in whom sulfonylureas or Takeda's Actos (pioglitazone) are not considered appropriate.
-
Takeda to pay $2.4bn to settle Actos cancer suits
Actos (pioglitazone) is licensed to help patients with type II diabetes reduce their sugar levels and has been on the market for more than 15 years.
More from news
Approximately 5 fully matching, plus 70 partially matching documents found.
Latest Intelligence
-
Interview: Trevor Smith, Takeda
Ulcer drug lansoprazole and prostate cancer treatment leuprorelin already faced generic competition and before the deal was completed Takeda's diabetes drug Actos (pioglitazone) lost exclusivity in January 2011.
-
Country report: The healthcare market in Japan
to its multi-billion dollar main product, the antidiabetic Actos (pioglitazone), in August. ... Takeda's patent on the blockbuster Actos (pioglitazone) for type 2 diabetes expired in January, but an agreement with generic drugmakers Ranbaxy, Watson and
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- World Health Organization releases latest set of COVID-19 guidelines
- BeiGene’s Brukinsa receives FDA approval for chronic lymphocytic leukaemia
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- Eli Lilly announces $450m investment in US manufacturing site
- Europe’s cancer community publishes new report on transforming patient care
- EU outlines measures to mitigate antibiotic shortage across Europe
- Innovative Trials comments on extra funding to increase access to clinical trials for cancer patients
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- JCVI recommends autumn COVID-19 vaccine booster for those at highest risk
- MIT researchers develop AI model to detect future lung cancer risk
- Merging global and local pharmacovigilance operations into a successful integrated approach
- Diversifying Healthcare AI with Federated Learning
- FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine
- World Health Organization releases latest set of COVID-19 guidelines
- AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement
- EU to revise pharmaceuticals law amid antibiotic shortages
- European MPs call for urgent action against antimicrobial resistance
- The role of medical communications in building credibility for healthtech
PMHub
An agency called Owen
We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....
Latest intelligence
- Virtual Steering Committee & Peer Influence Program
- In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
- Meeting healthcare’s rising challenges
- The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
- Report gives insights to address gaps in HCP engagement
- How does Pharma-HCP engagement need to evolve in today's digital landscape?...
